A study to evaluate the effect of a licensed drug to lower blood glucose, liraglutide, on inflammation in patients with diabetic kidney disease

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-005482-12

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Primary Objective: The primary objective of this study is to compare the change in pro-inflammatory cytokine monocyte-chemotactic protein 1 (MCP-1) in urine in subjects treated with liraglutide over a 26 week treatment period versus a matched control group who received no liraglutide.


Critère d'inclusion

  • Diabetic Kidney Disease

Liens